T. Rowe Price Associates
RVMDW icon

T. Rowe Price Associates’s Revolution Medicines Inc Warrant RVMDW Stock Holding History

T. Rowe Price Associates’s Portfolio RVMDW Stock Details RVMDW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.01M Sell
579,550
-16,384
-3% -$31.7K ﹤0.01% 2149
2025
Q4 		$555K Sell
595,934
-1
-0% -$1 ﹤0.01% 2343
2025
Q3 		$179K Sell
595,935
-3,366
-0.6% -$816 ﹤0.01% 2822
2025
Q2 		$162K Hold
599,301
– – ﹤0.01% 2782
2025
Q1 		$23K Sell
599,301
-6,879
-1% -$854 ﹤0.01% 2998
2024
Q4 		$97K Hold
606,180
– – ﹤0.01% 2836
2024
Q3 		$85K Hold
606,180
– – ﹤0.01% 2850
2024
Q2 		$43K Sell
606,180
-1,256
-0.2% -$260 ﹤0.01% 2869
2024
Q1 		$98K Sell
607,436
-1,038
-0.2% -$210 ﹤0.01% 2788
2023
Q4 		$201K Buy
+608,474
New +$272K ﹤0.01% 2544

Other funds holding RVMDW

LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

T. Rowe Price Associates's RVMDW Position: Q1 2026 in Review

T. Rowe Price Associates reduced its Revolution Medicines Inc Warrant (RVMDW) stake by 2.7% in Q1 2026, selling an estimated $31.7K and leaving 579,550 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #2149.

T. Rowe Price Associates first reported a position in RVMDW in Q4 2023 and has held it in 10 quarters since. 23 funds tracked by Wall St. Rank hold RVMDW as of Q1 2026.

  • T. Rowe Price Associates held 579,550 shares of Revolution Medicines Inc Warrant worth $1.01M as of Q1 2026.
  • T. Rowe Price Associates sold 16,384 Revolution Medicines Inc Warrant shares in Q1 2026, an estimated $31.7K.
  • Revolution Medicines Inc Warrant made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2149 holding.
  • T. Rowe Price Associates first reported a position in Revolution Medicines Inc Warrant in Q4 2023 and has held it in 10 quarters since.
  • 23 funds tracked by Wall St. Rank held Revolution Medicines Inc Warrant as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.